Efficacy and safety of neoadjuvant sintilimab plus chemotherapy for locally advanced resectable esophageal squamous cell carcinoma
- VernacularTitle:新辅助信迪利单抗联合化疗在局部晚期可切除食管鳞状细胞癌患者中的疗效和安全性
- Author:
Liji CHEN
1
;
Junjun HUANG
2
;
Hongmei MA
3
;
Shifa ZHANG
3
;
Dongbao YANG
3
;
Jiuhe SUN
3
;
Hongfeng LIU
3
;
Kaize ZHONG
3
;
Haibo CAI
3
Author Information
1. Department of Cardiac and Great Vessel Surgery, Jining No.1 People's Hospital, Jining, 272000, Shandong, P. R. China
2. Department of Thoracic Surgery, Huzhou Central Hospital, Huzhou, 313000, Zhejiang, P. R. China
3. Department of Thoracic Surgery, Jining No.1 People's Hospital, Jining, 272000, Shandong, P. R. China
- Publication Type:Journal Article
- Keywords:
Esophageal squamous cell carcinoma;
sintilimab;
neoadjuvant therapy;
PD-1 inhibitor;
pathological complete response;
major pathological response
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2026;33(07):1071-1078
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the efficacy and safety of neoadjuvant sintilimab combined with chemotherapy in the treatment of patients with locally advanced resectable esophageal squamous cell carcinoma (ESCC). Methods Clinical data were collected from patients with locally advanced resectable ESCC who received neoadjuvant immunotherapy combined with chemotherapy followed by surgical treatment at the Department of Thoracic Surgery of Jining No.1 People's Hospital from April 2020 to April 2022. The endpoints included major pathological response (MPR), pathological complete response (pCR), R0 resection rate, safety, and postoperative survival. Results A total of 43 patients with ESCC who received at least one cycle of neoadjuvant immunotherapy before surgery were included. Among them, there were 31 males and 12 females with a median age of 65 years (interquartile range: 58-69). All patients successfully completed the surgery without any surgical delays. The pCR rate was 14.0% (6/43), the MPR rate was 58.1% (25/43), and the R0 resection rate was 97.7% (42/43). Patients exhibited reliable safety during neoadjuvant therapy and postoperatively. The 2-year overall survival and disease-free survival rates were 90.7% and 81.4%, respectively. Kaplan-Meier survival analysis and log-rank test revealed lower recurrence rates and better survival in the MPR patients compared to the non-MPR patients. Conclusion The combination of neoadjuvant sintilimab and chemotherapy in the treatment of patients with locally advanced resectable ESCC has demonstrated significant clinical efficacy, while also being safe and reliable.
